E3 PreliminaryPreliminaryPEM unclearCase-ControlPeer-reviewedMachine draft
A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid.
Baraniuk, James N, Casado, Begona, Maibach, Hilda et al. · BMC neurology · 2005 · DOI
Quick Summary
Researchers examined fluid from around the spine (cerebrospinal fluid) in people with ME/CFS and found specific proteins that were present in patients but absent in healthy people. Using advanced laboratory techniques, they identified a set of 5 key proteins that could correctly identify ME/CFS in 80% of cases. These findings suggest ME/CFS may involve immune system and brain inflammation, offering hope for an objective test in the future.
Why It Matters
This study provides potential biological evidence for ME/CFS by identifying a specific protein signature in cerebrospinal fluid, suggesting objective diagnostic markers may exist. The findings support the hypothesis that ME/CFS involves central nervous system and immune dysfunction, which could guide future therapeutic development and help distinguish ME/CFS from other conditions with similar symptoms.
Observed Findings
- Five proteins (alpha-1-macroglobulin, amyloid precursor-like protein 1, keratin 16, orosomucoid 2, and pigment epithelium-derived factor) predicted CFS status with 80% concordance in logistic regression analysis.
- Twenty proteins were detected in pooled CFS and Persian Gulf War Illness samples but completely absent in pooled control samples.
- Ten proteins identified in cohort 1 were independently detected in individual CFS samples from cohort 2, but not in controls.
- Sixty-two of 115 identified proteins were newly described in cerebrospinal fluid.
Inferred Conclusions
- Central nervous system, innate immune, and amyloidogenic proteins are differentially present in cerebrospinal fluid of CFS patients and may represent a shared pathophysiological mechanism.
- CFS, Persian Gulf War Illness, and fibromyalgia may share overlapping biological pathology despite different clinical names and definitions.
- Cerebrospinal fluid proteomics may offer potential for developing an objective biomarker-based diagnostic test for ME/CFS.
Remaining Questions
- Do these proteins have functional roles in CFS pathology or are they merely markers of downstream disease processes?
- Will a larger, prospectively validated study confirm the 5-protein signature's diagnostic accuracy in diverse patient populations?
What This Study Does Not Prove
This pilot study does not prove these proteins cause ME/CFS or establish a definitive diagnostic test—further validation in larger, independent populations is required before clinical application. The study does not clarify whether these protein changes are primary drivers of illness or secondary consequences of disease. Pooling samples in cohort 1 limits individual-level inference and the small sample sizes reduce generalizability.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory OnlyMixed Cohort
Metadata
- DOI
- 10.1186/1471-2377-5-22
- PMID
- 16321154
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →